XOMA Corp (NASDAQ:XOMA)

25.80
Delayed Data
As of Feb 20
 -0.10 / -0.39%
Today’s Change
4.50
Today|||52-Week Range
37.25
-27.53%
Year-to-Date
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
Feb 19 / Zacks.com - Paid Partner Content
AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
Feb 14 / Zacks.com - Paid Partner Content
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
Feb 16 / Zacks.com - Paid Partner Content
Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling
Feb 14 / Zacks.com - Paid Partner Content
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
Feb 16 / Zacks.com - Paid Partner Content
Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval
Feb 13 / Zacks.com - Paid Partner Content
Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up
Feb 16 / Zacks.com - Paid Partner Content
ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow
Feb 12 / Zacks.com - Paid Partner Content
Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates
Feb 15 / Zacks.com - Paid Partner Content
FDA Okays J&J's Prostate Cancer Drug in First-Line Setting
Feb 09 / Zacks.com - Paid Partner Content
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View
Feb 15 / Zacks.com - Paid Partner Content
Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
Feb 08 / Zacks.com - Paid Partner Content
Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y
Feb 15 / Zacks.com - Paid Partner Content
Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4
Feb 08 / Zacks.com - Paid Partner Content
Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses
Feb 15 / Zacks.com - Paid Partner Content
Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down
Feb 08 / Zacks.com - Paid Partner Content
Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong
Feb 15 / Zacks.com - Paid Partner Content